FENC Share Price Performance
US$7.78
3.30 (73.66%)
48.1% undervalued intrinsic discount
US$15.00
Fair Value
Price US$7.78
AnalystHighTarget US$15.00
AnalystLowTarget US$13.00
AnalystConsensusTarget US$13.80
Fair ValueUS$15.00
Share Pricen/a
Fennec Pharmaceuticals Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
FENC Community Narratives
AN
Fair Value US$15 48.1% undervalued intrinsic discount
Secular Trends Will Expand Global Adoption Of PEDMARK In Oncology
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$13 40.2% undervalued intrinsic discount
Single Product Reliance Will Trigger Setbacks But Potential Remains
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$14 44.4% undervalued intrinsic discount
Expanding Global Supportive Cancer Care Will Unlock Future Opportunities
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Expanding Global Supportive Cancer Care Will Unlock Future Opportunities
Key Takeaways Expanding into new patient segments and global markets is fueling strong revenue growth and increasing adoption of PEDMARK® through strategic partnerships and investments. Positive regulatory developments and operational efficiencies are expected to improve margins, enable further product expansion, and support a move toward sustainable profitability.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$14
44.4% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
44.64% p.a.
Profit Margin
40.69%
Future PE
12.06x
Share price in 2028
US$17.01
Single Product Reliance Will Trigger Setbacks But Potential Remains
Key Takeaways Heavy reliance on a single drug and exposure to pricing pressure threaten margin stability and make future revenue growth dependent on successful pipeline expansion. Expansion into new demographics and regions offers growth potential, but slow adoption, regulatory hurdles, and resource limits may restrain market penetration and earnings.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$13
40.2% undervalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
49.19% p.a.
Profit Margin
42.96%
Future PE
10.05x
Share price in 2028
US$15.6
Secular Trends Will Expand Global Adoption Of PEDMARK In Oncology
Key Takeaways Accelerated PEDMARK adoption, global launches, and strong field execution could drive much faster than expected revenue, earnings, and margin growth. Scale, disciplined cost controls, and emerging market leadership may deliver early profitability and underpin long-term growth through pipeline expansion and strategic deals.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$15
48.1% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
58.26% p.a.
Profit Margin
53.78%
Future PE
7.76x
Share price in 2028
US$18.01
Snowflake Analysis
Fennec Pharmaceuticals Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.43
- 89.89%
- -36.14%
- -259.5%
About FENC
- Founded
- 1996
- Employees
- 32
- CEO
- WebsiteView website
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
